Bipolar Disorder Market Size, Share, Growth Analysis, By Drug Class(Mood Stabilizers, Anticonvulsants, Antipsychotic Drugs, Antidepressant Drugs), By Type(Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder, Others), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35I2095 | Region: Global | Published Date: July, 2001
Pages: 157 |Tables: 67 |Figures: 75

Bipolar Disorder Market Insights

Bipolar Disorder Market size was valued at USD 5.36 Billion in 2023 and is poised to grow from USD 5.47 Billion in 2024 to USD 6.53 Billion by 2032, growing at a CAGR of 2.00% during the forecast period (2025-2032).

Manic depression, formerly known as bipolar disorder is a mental health illness that results in sharp mood swings, including emotional highs (mania or hypomania), and lows (depression). According to research, the fact that bipolar disorder frequently runs in families and that some people are more predisposed to the condition than others due to certain genes. No single gene can cause the condition; multiple genes are involved.

Three distinct diagnoses fall under the category of bipolar disorder bipolar I, bipolar II, and cyclothymic disorder. According to a recent study, India has the lowest lifetime risk of bipolar disorder at 0.1% and the United States has the highest rate at 4.4%.

A few of the factors boosting the growth of this market include the rising prevalence of bipolar illness, government assistance for raising awareness about the condition, and technology advancements that enable precise detection of a patient's mood and mental state. In contrast to other medications used to treat bipolar disorder, the use of tricyclic antidepressants has decreased over time as a result of their higher prevalence of side effects.

US Bipolar Disorder Market  is poised to grow at a sustainable CAGR for the next forecast year.

To get more reports on the above market click here to Buy The Report

Bipolar Disorder Market Segmental Analysis

Global bipolar disorder market is segmented based on the drug class, type, and region. Based on the drug class, the global market is segmented as mood stabilizers, anticonvulsants, antipsychotic drugs, antidepressant drugs, antianxiety drugs and others. Based on type, the market is segmented as, bipolar I disorder, bipolar II disorder, cyclothymic disorder, and others. Based on region, the market is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.

Bipolar Disorder Market Analysis by Drug Class

Based on drug class, the market is segmented into mood stabilizers, anticonvulsants, antipsychotic drugs, antidepressant drugs, and antianxiety drugs and dominated by the antipsychotic medication category. SSRIs and antipsychotic medications can be used together in combination therapy. The majority of medical experts choose antipsychotic medications because they outperform other over-the-counter bipolar medications in the market in terms of effectiveness.

The majority of the revenue generated by the global market for bipolar disorder medications and treatments is anticipated to derive from this category. Over the course of the forecast period, it is anticipated to expand at a CAGR of 2.8%, which is higher than the other market categories. By 2027, the market for antipsychotic medications is anticipated to be worth USD 3 Bn.
Anticonvulsant medications are currently being used by doctors more frequently, resulting in a CAGR of 3.9% over the forecast period.

Bipolar Disorder Market Analysis by Type

Global bipolar disorder market has been segmented on the basis of type as bipolar I disorder, bipolar II disorder, cyclothymic disorder and others. Among these, the bipolar I disorder category is now in the lead with the largest market share. The largest proportions are largely due to the rise in chronic illness cases among persons who are under escalating amounts of stress. The market sector with the greatest market shares in second place is bipolar II disorders.

To get detailed analysis on other segments, Request For Free Sample Report

Bipolar Disorder Market Regional Insights

Geographically, North America is anticipated to dominate the global bipolar disorder market due to the region's high levels of stress and widespread substance misuse problems. Various government programmes and efforts meant to increase awareness fuel the rise of the market in Europe and North America. The North America region demonstrated its dominance by accounting for over 50% of the global market for bipolar disorder in 2019 and anticipated for the forecast period. The market demand is significantly rising due to the Y-O-Y increase in the prevalence of bipolar disorder in this region. The prevalence of bipolar disorder is rising in the North America, which is driving the regional market. A sizeable portion of the population in this region has high levels of stress and sleep problems.

Recently, governments in North America have launched a number of initiatives to raise public awareness of bipolar disorder, which is further anticipated to support market expansion.

Due to the high prevalence of mental diseases in this region, Asia Pacific is also anticipated to see a greater CAGR over the course of the projected period than other regions. India and China are among the nations with the highest rates of mental illnesses like anxiety, schizophrenia, and bipolar disorder, according to WHO data. Along with government initiatives, the market in this region is projected to be driven by APEC's Healthy Asia Pacific 2020 initiative, which was launched in 2014.

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Bipolar Disorder Market Dynamics

Bipolar Disorder Market Drivers

Emphasis on improving product portfolio and the growing number of mental illnesses is expected to propel the market growth

  • The market for treating bipolar illness is anticipated to rise over the forecast period as key players concentrate on expanding their product portfolio through an increase in the launches and approvals of new pharmaceuticals for the condition. For instance, in May 2019, the U.S. Food and Drug Administration (FDA) approved Allergan plc and Gedeon Richter plc's supplemental new drug application (sNDA) for VRAYLAR (cariprazine), an oral, once-daily atypical antipsychotic drug for the expanded use and treatment of depressive episodes related to bipolar I disorder (bipolar depression) in adults.
  • Bipolar disorder prevalence is rising, there are more government efforts to raise public awareness of its consequences, there is a strong demand for antidepressants, and there is a desire to lessen the illness burden of bipolar disorder. 

Bipolar Disorder Market Restraints

Lack of medications and the correct line of treatment to create market challenges

  • The patent expirations of several key products, including Latuda (lurasidone) from Sumitomo Dainippon Pharma and Sunovion Pharmaceuticals, Abilify Maintena (aripiprazole ER) from Otsuka Pharmaceutical and Lundbeck, and Risperdal Consta (risperidone PR) from Johnson and Johnson, are expected to further increase the constraints in the bipolar disorder market during the forecast period. Lithium is one example of a generic drug with high usage that is anticipated to last the entire projected period.
  • Lack of appropriate diagnostic methods for the diagnosis of the disease and the negative side effects of treatments for bipolar disorder are anticipated to restrain market expansion. On the other hand, developments in drug combination therapy offer profitable prospects for market expansion in the near future.

Request Free Customization of this report to help us to meet your business objectives.

Bipolar Disorder Market Competitive Landscape

Global bipolar disorder market is relatively fragmented, with a high level of competition. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective solutions.

Top Players in the Global Bipolar Disorder Market

  • Allergan (Ireland)
  • AstraZeneca plc
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals Inc. (a subsidiary of Johnson & Johnson)
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Abbott Laboratories
  • Novartis International AG
  • Alkermes plc
  • AbbVie Inc.
  • Merck & Co. Inc.
  • Mylan N.V.
  • Neurocrine Biosciences Inc.
  • Vanda Pharmaceuticals Inc.

Bipolar Disorder Market Recent Developments

  • In January 2022, the U.S. Food and Drug Administration (FDA) approved an expanded indication for the antipsychotic Caplyta (lumateperone) for the treatment of bipolar I and II depression in adults. Caplyta, marketed by Intra-Cellular Therapies Inc., was already approved for the treatment of schizophrenia in adults.

     

  • In June 2021, Through the multi-stage ENLIGHTEN clinical trials, the Food and Drug Administration (FDA) approved Lybalvi® (olanzapine/samidorphan) for a number of indications, including the treatment of adults with schizophrenia and/or bipolar I disorder (acute manic episodes or acute episodes with mixed features). Olanzapine/safety samidorphan's and effectiveness were examined over studies lasting 4 weeks, 24 weeks, and 52 weeks, respectively. The secondary analysis further assessed the metabolic consequences.

Bipolar Disorder Key Market Trends

  • Rising cases of mental illness: As non-ambiguous cases of illness have been increasingly prevalent in the population, bipolar disorder in children and adolescents has become a common diagnosis.
  • Technological Advancements: With the improvements in monitoring techniques, professionals can effectively advise the line of treatment based on close observations.

Bipolar Disorder Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected utilizing Primary Exploratory Research backed by the robust Secondary Desk research.

According to the global bipolar disorder market report analysis, in terms of drug class in which anticonvulsant medications are currently being used by doctors more frequently, resulting in a CAGR of 3.9% over the forecast period.

Some of the greatest over-the-counter medications for treating bipolar disorder are carbamazepine, also known as Equetro, divalproex sodium, also known as Depakote, lamotrigine, also known as Lamictal, topiramate, also known as Topamax, and valproic acid, also known as Depakene. As previously indicated, all of these anticonvulsant medications are currently responsible for 32% of the world's market for bipolar treatment pharmaceuticals and are anticipated to grow at a CAGR of 3.9% collectively.

Report Metric Details
Market size value in 2023 USD 5.25 billion
Market size value in 2031 USD 6.4 billion
Growth Rate 2.00%
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Drug Class
    • Mood Stabilizers, Anticonvulsants, Antipsychotic Drugs, Antidepressant Drugs, Antianxiety Drugs, Other
  • Type
    • Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder, Others
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Allergan (Ireland)
  • AstraZeneca plc
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals Inc. (a subsidiary of Johnson & Johnson)
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Abbott Laboratories
  • Novartis International AG
  • Alkermes plc
  • AbbVie Inc.
  • Merck & Co. Inc.
  • Mylan N.V.
  • Neurocrine Biosciences Inc.
  • Vanda Pharmaceuticals Inc.
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

Historical Year 2019

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Bipolar Disorder Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Bipolar Disorder Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Bipolar Disorder Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Bipolar Disorder Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Bipolar Disorder Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Bipolar Disorder Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?
REQUEST FREE CUSTOMIZATION

FAQs

Bipolar Disorder Market size was valued at USD 5.25 billion in 2019 and is poised to grow from USD 5.36 billion in 2023 to USD 6.4 billion by 2031, growing at a CAGR of 2.00% in the forecast period (2024-2031).

bipolar disorder market is relatively fragmented, with a high level of competition. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective solutions. 'Allergan (Ireland)', 'AstraZeneca plc', 'Bristol Myers Squibb Company', 'Eli Lilly and Company', 'GlaxoSmithKline plc', 'H. Lundbeck A/S', 'Janssen Pharmaceuticals Inc. (a subsidiary of Johnson & Johnson)', 'Otsuka Holdings Co. Ltd.', 'Pfizer Inc.', 'Sunovion Pharmaceuticals Inc.', 'Teva Pharmaceutical Industries Ltd.', 'Takeda Pharmaceutical Company Limited', 'Abbott Laboratories', 'Novartis International AG', 'Alkermes plc', 'AbbVie Inc.', 'Merck & Co. Inc.', 'Mylan N.V.', 'Neurocrine Biosciences Inc.', 'Vanda Pharmaceuticals Inc.'

The market for treating bipolar illness is anticipated to rise over the forecast period as key players concentrate on expanding their product portfolio through an increase in the launches and approvals of new pharmaceuticals for the condition. For instance, in May 2019, the U.S. Food and Drug Administration (FDA) approved Allergan plc and Gedeon Richter plc's supplemental new drug application (sNDA) for VRAYLAR (cariprazine), an oral, once-daily atypical antipsychotic drug for the expanded use and treatment of depressive episodes related to bipolar I disorder (bipolar depression) in adults.

Rising cases of mental illness: As non-ambiguous cases of illness have been increasingly prevalent in the population, bipolar disorder in children and adolescents has become a common diagnosis.

Geographically, North America is anticipated to dominate the bipolar disorder market due to the region's high levels of stress and widespread substance misuse problems. Various government programmes and efforts meant to increase awareness fuel the rise of the market in Europe and North America. The North America region demonstrated its dominance by accounting for over 50% of the market for bipolar disorder in 2019 and anticipated for the forecast period. The market demand is significantly rising due to the Y-O-Y increase in the prevalence of bipolar disorder in this region. The prevalence of bipolar disorder is rising in the North America, which is driving the regional market. A sizeable portion of the population in this region has high levels of stress and sleep problems.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Bipolar Disorder Market

Report ID: SQMIG35I2095

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE